Antibody Treatment Proves Effective for Bile Duct Cancers

An antibody treatment helped shrink tumors in some patients with bile duct cancers.

In patients with bile duct cancers, antibody treatment using zanidatamab was found to help shrink tumors, revealed study published in The Lancet Oncology ().

What is Bile Duct Cancer?

Bile duct cancers are uncommon and aggressive types of gastrointestinal cancer (). They include cholangiocarcinomas, which can form inside or outside of the liver, as well as cancers of the gallbladder, and are highly likely to cause serious disease or //prove fatal.

Bile duct cancers affect the biliary tract, which consists of organs and ducts that make and store bile and release it into the small intestine. They are known as “silent” cancers, because there are usually no symptoms until they reach later stages. Surgery can be effective if bile duct cancer is caught early, but for most patients there are few good treatments.

Bile Duct Cancer | Cholangiocarcinoma - Causes, Risk Factors, Symptoms, Diagnosis, Stages, Treatment, Support Groups
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the liver or outside the liver.

‘An antibody treatment helped shrink tumors in some patients with bile duct cancers.’

The phase 2b clinical trial, known as HERIZON-BTC-01 (), was a global, multicenter effort to evaluate the effectiveness and safety of zanidatamab, an antibody that works against the HER2 protein, in patients with HER2-amplifed bile duct cancer that has not responded to other treatment. Gastrointestinal oncologist James Harding, MD, of Memorial Sloan Kettering Cancer Center (MSK), and Fan Jia, Director of the Liver Cancer Institute at Fudan University in China, served on the trial’s steering committee and were co-first authors of The Lancet Oncology study.

“Incidence of bile duct cancer has been on the rise in recent decades,” Dr. Harding says. “There are currently no approved therapies targeting HER2 in these cancers, and therefore there is a significant unmet medical need. The results of this trial are very encouraging — zanidatamab shrank tumors in a subset of patients with HER2-positive disease and was well-tolerated overall. The study illustrates the importance of molecular profiling of these cancers to allow us to match patients to precision medicines that target the features of their individual cancer.”

Clinical Trial Results Using Zanidatamab Against HER2-Amplified Bile Duct Cancers

The study enrolled 87 participants with HER2-amplified biliary tract cancers that were locally advanced or had spread throughout the body and for whom chemotherapy had stopped working. The patients received zanidatamab intravenously (by IV) every two weeks. The antibody binds to HER2 receptors and leads to a decrease of HER2 on the surface of the cancer cells, helping to slow down their runaway growth.

The treatment was effective in shrinking tumors in 41% of the patients, the trial found. Half of patients had responses within 1.8 months, and these responses lasted 12.9 months or more in half of the patients who responded to the drug. Doctors continue to follow these patients to assess the impact of the treatment over a longer period of time, the study authors note.

Key Pathway in Bile Duct Cancer Discovered
A key pathway, called wnt, that drives tumor growth in bile duct cancer has been discovered and a new class of experimental drug could help the patients with bile duct cancer.

The most common side effects of the treatment were diarrhea (37% of participants) and infusion-related reactions, such as allergic reactions, pain at the injection site, nausea, or flu-like symptoms (33% of participants). A small number of people had a decrease in heart function. No severe side effects were reported.

Zanidatamab remains under investigation and will undergo additional study to test the antibody’s safety and effectiveness in a larger group of people, the researchers note. The antibody is also being evaluated in combination with first-line chemotherapies, as well as for patients with other types of HER2-expressing tumors.

How Precision Therapy for Bile Duct Cancer Extend Patients' Lives
Patients with bile duct cancer who were otherwise facing end of life care survived for up to two years when treated with the drug futibatinib.

The data from the trial support the potential of zanidatamab as a new targeted therapy when patients don’t respond to chemotherapy, the study authors write.

“Continued research in evaluation of HER2-targeted therapies in HER2-positive biliary tract cancers is essential to improve care for these patients,” Dr. Harding says. “MSK has led the development of many of these therapies over the last several decades in multiple solid tumors, and there are several ongoing studies happening in New York City and across MSK’s regional sites. Moreover, we have a robust program with highly experienced surgeons in surgery for early stages of disease, and experts in radiation therapy, chemotherapy, and minimally invasive symptom relief for more advanced disease, as well as access to the latest clinical trials.”

Bile Duct Cancer Gets a New Drug Treatment Using Genomic Sequencing Technique
Personalized drug treatments are being done for patients suffering from cholangiocarcinoma using genomic sequencing technologies by physicians at the Mayo Clinic

References:

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study - (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00242-5/fulltext)
Bile Duct Cancer (Cholangiocarcinoma) Treatment - (https://www.mskcc.org/cancer-care/types/bile-duct-cancer-cholangiocarcinoma/treatment)
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) - (https://clinicaltrials.gov/ct2/show/NCT04466891)

Source-Eurekalert